Bozinoff, Nikki http://orcid.org/0000-0001-9512-7407
Kleinman, Robert A.
Sloan, Matthew E.
Kennedy, Mary Clare
Nolan, Seonaid
Selby, Peter
Kalocsai, Csilla
Wood, Evan
Article History
Received: 20 October 2023
Accepted: 16 January 2024
First Online: 29 January 2024
Declarations:
:
: None required.
: Dr. Bozinoff has received research grant support from Womenmind, the Academic Health Sciences Alternate Funding Program and the Canadian Institutes of Health Research (CIHR) and salary support from US National Institute on Drug Abuse (NIDA) grant R25-DA037756. She has received honoraria for continuing professional development talks from the Ontario College of Family Physicians. Dr. Kleinman reports no conflicts of interest.Dr. Sloan’s work is supported in part by an Academic Scholar Award from the Department of Psychiatry, University of Toronto. He reports research grant funding from CIHR, the Academic Health Sciences Alternate Funding Program, CAMH Discovery Fund, the Ontario Ministry of Health and Longterm Care. He has received honoraria for a talk given to the Department of Psychiatry at the McGill University Health Centre. Dr. Mary Clare Kennedy reports no conflicts of interest. Dr. Seonaid Nolan reports no conflicts of interest. Dr. Peter Selby holds the Vice Chair Research and Giblon Professor in Family Medicine Research, a University named Professorship at the University of Toronto. He reports research grants from CAMH, Health Canada, Ontario Ministry of Health and Long-Term Care, CIHR, Canadian Centre on Substance Abuse, Public Health Agency of Canada, Pfizer Inc./Canada, Ontario Lung Association, Medical Psychiatry Alliance, ECHO, Canadian Cancer Society Research Institute, Cancer Care Ontario, Ontario Institute Cancer Research, Ontario Brain Institute, McLaughlin Centre, Alternate Funding Plans for Academic Health Science Centres, Workplace Safety Insurance Board, National Institutes of Health, Association of Faculties of Medicine of Canada, Shoppers Drug Mart, Bhasin Consulting Fund Inc., and the Patient-Centered Outcomes Research Institute. He reports receiving consulting fees from Pfizer Canada Inc., Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Inflexxion Inc., V-CC Systems Inc., MedPlan Communications, Kataka Medical Communications, Miller Medical Communications, NVision Insight Group, Sun Life Financial, Myelin & Associates. He reports honoraria for speaking engagements from Canadian Partnership Against Cancer; Toronto Public Health; Ontario Association of Public Health Dentistry; ECHO; Pfizer Canada Inc., ABBVie, and Bristol-Myers Squibb. He reports receiving free/discounted strudy drugs through open tender process from Johnson & Johnson, Novartis, Pfizer Inc. Dr. Evan Wood is supported by a Canadian Institutes of Health Research Tier 1 Canada Research Chair, and has received salary support from an R01 from NIDA, paid to UBC. Dr. Wood’s research lab is further supported by CIHR grants to the Canadian Research Initiative in Substance Misuse. Dr. Wood has also undertaken consulting work in legal matters related to substance use disorders and for a mental health company called Numinus Wellness, where Dr. Wood is former chief medical officer; Dr. Wood has also received compensation in the form of equity in Numinus. Dr. Wood reports receiving honoraria for non-industry related lectures and presentations (e.g., at academic or educational conferences), including a talk at the Canadian Society of Addiction Medicine (CSAM) paid by CSAM conference; a Rounds Presentation at Dalhousie University (paid by the University); and an educational talk for the allied health educational platform, Executive Links (all outside the submitted work and did not involve funding from the pharmaceutical industry). Dr. Wood has also received payment for expert reports and expert testimony in legal matters pertaining to substance use disorder, including from the Canadian Medical Protective Association and from trade unions representing workers with possible substance use disorder. Dr. Wood has received travel support from the CIHR.Mary Clare Kennedy is supported by the Canada Research Chairs program through a Tier 2 Canada Research Chair in Substance Use Policy and Practice Research [2021-00272].
: The case used is a blended case study based on the authors’ own experiences managing clients with substance use disorders and does not represent patient health information.
Free to read: This content has been made available to all.